Professional Documents
Culture Documents
NIFTY - REPORT 01 December Equity Research Lab
NIFTY - REPORT 01 December Equity Research Lab
uiopasdfghjklzxcvbnmqwertyuiopasd
fghjklzxcvbnmqwertyuiopasdfghjklzx
cvbnmqwertyuiopasdfghjklzxcvbnmq
wertyuiopasdfghjklzxcvbnmqwertyui
opasdfghjklzxcvbnmqwertyuiopasdfg
hjklzxcvbnmqwertyuiopasdfghjklzxc
vbnmqwertyuiopasdfghjklzxcvbnmq
wertyuiopasdfghjklzxcvbnmqwertyui
opasdfghjklzxcvbnmqwertyuiopasdfg
NIFTY OUTLOOK
hjklzxcvbnmqwertyuiopasdfghjklzxc
REPORT
vbnmqwertyuiopasdfghjklzxcvbnmq
1 December 2016
wertyuiopasdfghjklzxcvbnmqwertyui
Prepared by: Meenakshi Pal
opasdfghjklzxcvbnmqwertyuiopasdfg
hjklzxcvbnmrtyuiopasdfghjklzxcvbn
mqwertyuiopasdfghjklzxcvbnmqwert
yuiopasdfghjklzxcvbnmqwertyuiopas
st
NIFTY FUTURE
NIFTY FUTURE :
PIVOT :8232
R1:8298
S1:8194
R2:8336
S2:8128
R3:8402
S3:8089
INDEX OUTLOOK
NIFTY FUTURE: The key benchmark extended their gains in the late afternoon session and was hovering
near the highest point of the day on continued buying by domestic institutional investors amid higher
opening among European counterparts. Sentiments remained upbeat on expectations of positive GDP
data to be released later in the day. Further, Oil markets edged up ahead of an OPEC meeting later in
the day, with members of the producer cartel trying to thrash out an output cut to curb oversupply that
has seen prices more than halve since 2014. Nifty closed 82.35 points higher at 8,224.50. The India
VIX index was down 4.84% at 16.8500. The BSE Midcap closed at 12498.62 and Smallcap indices
closed at 12329.65, both indices ending up by 1%. The rupee was trading at 68.48 per US dollar. On
the global front, most Asian indices closed in green and marginally up. where all indices were trading
WWW.EQUITYRESEARCHLAB.COM
in green while, the US Nasdaq was also up 0.21%.
STRATEGY: Buy Nifty Future above 8270 for the target of 8320 -8370 with the stop loss of 8200.
SECTORAL INDICES
INDEX
(Spot)
SENSEX
NIFTY
NIFTYBANK
NIFTYIT
SUPPORT 2
26250
8100
18200
9890
CORPORATE NEWS
Vivimed Labs closed higher by 7% after the company stated that the US health regulator has
completed the inspection of its manufacturing facility in Alathur. The companys Finished Dosage
Form manufacturing facility has had a favorable outcome post its US Food and Drug Administration
(USFDA) inspection.
Lupin Ltd stated that it has received approval from the US health regulator to market its Armodafinil
tablets, indicated to improve wakefulness, in the US market.
Idea Cellular Ltd fell 2% to Rs77.3 after the company said in a notice to BSE that the media reports
that the company looking to sell 20% stake is just a speculation.
WWW.EQUITYRESEARCHLAB.COM
Designation
E-mail ID
Research Head
Sr. Research Analyst
Sr. Research Analyst
Tuhinanshu.jain@equityresearchlab.co.in
Yogesh.subnani@equityresearchlab.co.in
Meenakshi.pal@equityresearchlab.co.in
DISCLAIMER
The information and views in this report, our website & all the service we provide are believed to be
reliable, but we do not accept any responsibility (or liability) for errors of fact or opinion. Users have
the right to choose the product/s that suits them the most. Investment in Stocks has its own risks.
Sincere efforts have been made to present the right investment perspective. The information contained
herein is based on analysis and up on sources that we consider reliable. We, however, do not vouch
for the accuracy or the completeness thereof. This material is for personal information and we are not
responsible for any loss incurred based upon it & takes no responsibility whatsoever for any financial
profit s or loss which may arise from the recommendations above. The stock price projections shown
are not necessarily indicative of future price performance. The information herein, together with all
estimates and forecasts, can change without notice.
Equity Research Lab does not purport to be an invitation or an offer to buy or sell any financial
instrument. Analyst or any person related to Equity Research Lab might be holding positions in the
stocks recommended. It is understood that anyone who is browsing through the site has done so at his
free will and does not read any views expressed as a recommendation for which either the site or its
owners or anyone can be held responsible for. Any surfing and reading of the information is the
acceptance of this disclaimer.
Our Clients (Paid or Unpaid), any third party or anyone else have no rights to forward or share our
calls or SMS or Report or Any Information Provided by us to/with anyone which is received directly
or indirectly by them. If found so then Serious Legal Actions can be taken. Any surfing and reading of
the information is the acceptance of this disclaimer.
ALL RIGHTS RESERVED.
WWW.EQUITYRESEARCHLAB.COM